Oppenheimer restated their outperform rating on shares of Portola Pharmaceuticals (NASDAQ:PTLA) in a research report sent to investors on Tuesday morning.

Other analysts also recently issued research reports about the stock. BidaskClub raised shares of Portola Pharmaceuticals from a strong sell rating to a sell rating in a research report on Thursday, December 21st. Goldman Sachs Group started coverage on shares of Portola Pharmaceuticals in a research report on Friday, December 1st. They issued a buy rating and a $75.00 price objective for the company. Morgan Stanley reaffirmed an overweight rating and issued a $81.00 price objective (up previously from $75.00) on shares of Portola Pharmaceuticals in a research report on Friday, October 6th. William Blair reaffirmed a buy rating on shares of Portola Pharmaceuticals in a research report on Monday. Finally, Citigroup reaffirmed a buy rating and issued a $74.00 price objective on shares of Portola Pharmaceuticals in a research report on Thursday, December 28th. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $70.65.

Portola Pharmaceuticals (NASDAQ PTLA) traded down $0.57 on Tuesday, reaching $48.84. 650,400 shares of the company were exchanged, compared to its average volume of 1,156,400. The firm has a market cap of $3,150.00, a P/E ratio of -11.31 and a beta of 1.21. Portola Pharmaceuticals has a 12-month low of $23.70 and a 12-month high of $67.10. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31.

Portola Pharmaceuticals (NASDAQ:PTLA) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.49) by $0.08. The firm had revenue of $3.83 million during the quarter, compared to the consensus estimate of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. The company’s revenue was down 58.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.64) EPS. analysts expect that Portola Pharmaceuticals will post -4.94 EPS for the current year.

In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $47.00, for a total value of $564,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.50% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in PTLA. Renaissance Technologies LLC purchased a new position in shares of Portola Pharmaceuticals during the 2nd quarter valued at approximately $21,187,000. Kornitzer Capital Management Inc. KS lifted its stake in Portola Pharmaceuticals by 38.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock worth $39,324,000 after purchasing an additional 202,925 shares during the last quarter. Zevenbergen Capital Investments LLC lifted its stake in Portola Pharmaceuticals by 71.4% during the second quarter. Zevenbergen Capital Investments LLC now owns 452,190 shares of the biopharmaceutical company’s stock worth $25,400,000 after purchasing an additional 188,320 shares during the last quarter. Blue Jay Capital Management LLC bought a new position in Portola Pharmaceuticals during the second quarter worth $6,740,000. Finally, State Street Corp lifted its stake in Portola Pharmaceuticals by 5.3% during the second quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock worth $117,164,000 after purchasing an additional 105,207 shares during the last quarter. Institutional investors own 87.25% of the company’s stock.

WARNING: “Oppenheimer Reaffirms Outperform Rating for Portola Pharmaceuticals (PTLA)” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://theolympiareport.com/2018/01/05/oppenheimer-reaffirms-outperform-rating-for-portola-pharmaceuticals-ptla.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.